Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data.
Results of treatment for patients with non-Hodgkin's lymphomas have significantly improved over the last decade, especially following the discovery that anti-CD20 antibody therapy can significantly change the outlook for patients with both aggressive and indolent lymphomas. Although investigators have previously attempted to prevent relapses by intensifying chemotherapy programs for patients with poor-risk disease, further improvements in treatment will require development of biologic agents that can be added to current programs and exploitation of currently available drugs that can prevent recurrence of these diseases with good tolerability. This review analyzes currently available plans that can be used to maintain responses or "consolidate" initial responses to therapy, programs that may prevent relapse and potentially cure more patients with lymphomas, with a review of current ongoing trials designed along these lines.
Hagemeister
Fredrick B
FB
Department of Lymphoma/Myeloma, M. D. Anderson Cancer Center, Houston, TX 77030, USA. fhagemei@mdanderson.org
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D019496:Cancer Vaccines / Q000008:administration & dosage; D003131:Combined Modality Therapy; D018450:Disease Progression; D018572:Disease-Free Survival; D000068338:Everolimus; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007211:Indoles / Q000008:administration & dosage; D000077269:Lenalidomide; D008228:Lymphoma, Non-Hodgkin / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D016499:Radioimmunotherapy; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D000069283:Rituximab; D055502:Secondary Prevention; D015398:Signal Transduction / Q000187:drug effects; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives; D015996:Survival Rate / Q000639:trends; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D019496:Cancer Vaccines; D007211:Indoles; D000069283:Rituximab; C422802:ibritumomab tiuxetan; D013792:Thalidomide; D000068338:Everolimus; D011505:Protein-Tyrosine Kinases; D000077269:Lenalidomide; C119496:tositumomab I-131; C504878:enzastaurin; D020123:Sirolimus
Blood. 2005 Dec 1;106(12):3725-32
16123223
Oncogene. 2004 Apr 19;23(18):3151-71
15094765
Blood. 2008 Dec 15;112(13):4824-31
18799723
Cancer. 2008 Nov 15;113(10):2714-23
18853418
N Engl J Med. 2007 May 31;356(22):2271-81
17538086
J Clin Oncol. 1998 Aug;16(8):2825-33
9704735
Drugs. 2010 Feb 12;70(3):261-72
20166765
J Clin Oncol. 2001 Oct 1;19(19):3918-28
11579112
Clin Cancer Res. 2005 Jan 1;11(1):28-40
15671525
J Clin Oncol. 2007 May 1;25(13):1741-6
17389337
J Clin Oncol. 2005 Aug 10;23(23):5347-56
15983389
Leukemia. 2007 Feb;21(2):333-9
17136116
J Clin Oncol. 2005 Oct 20;23(30):7565-73
16186600
J Clin Oncol. 2005 Aug 20;23(24):5696-704
16110029
N Engl J Med. 2005 Feb 3;352(5):441-9
15689582
J Clin Oncol. 2005 Feb 1;23(4):712-9
15613695
Ann Oncol. 1998 Sep;9(9):995-1001
9818074
Br J Haematol. 2006 Sep;134(5):475-84
16856892
J Clin Oncol. 2005 Feb 20;23(6):1088-95
15657401
J Clin Oncol. 2009 Apr 1;27(10):1607-14
19255334
J Clin Oncol. 2010 Oct 10;28(29):4480-4
20697092
Blood. 2003 Oct 1;102(7):2351-7
12750161
Expert Rev Anticancer Ther. 2005 Jun;5(3):477-85
16001955
Cancer. 2010 Sep 15;116(18):4256-65
20549832
Cancer. 2008 Aug 1;113(3):508-14
18543327
J Clin Oncol. 2008 Nov 10;26(32):5156-64
18854568
J Clin Oncol. 2002 May 15;20(10):2453-63
12011122
Cancer Biother Radiopharm. 2005 Apr;20(2):185-8
15869453
Cancer Biol Ther. 2003 May-Jun;2(3):222-32
12878853
Cancer. 2006 Feb 1;106(3):616-22
16362977
J Clin Oncol. 2002 Aug 1;20(15):3262-9
12149300
Blood. 2005 Feb 15;105(4):1417-23
15494430
Cancer Control. 2005 Apr;12(2):91-104
15855892
J Clin Oncol. 2007 May 20;25(15):1986-92
17420513
J Clin Oncol. 2005 Feb 20;23(6):1096-102
15657402
J Clin Oncol. 2006 Sep 1;24(25):4143-9
16896003
J Clin Oncol. 2009 Jul 10;27(20):3346-53
19451441
J Natl Cancer Inst. 2006 Sep 20;98(18):1292-301
16985248
Blood. 2008 Jun 15;111(12):5486-95
18390837
Haematologica. 2007 Jun;92(6):826-33
17550856
Blood. 2004 Nov 15;104(10):3064-71
15284112
J Clin Oncol. 2002 Sep 15;20(18):3885-90
12228209
J Clin Oncol. 2010 Jun 10;28(17):2853-8
20439641
J Clin Oncol. 2008 Oct 20;26(30):4952-7
18606983
Blood. 2004 Jun 15;103(12):4416-23
14976046